ghk-cu immunogenicity antibodies neutralizing NeutraKine® GM-CSF antibody (69003-1-Ig) Anti-drug antibodies may intrinsically be
Description
Guerrouahen, B
ATF4, activating transcription factor 4
The evidence for KLOW is indirect : it rests on preclinical research into the individual components, not on the blend
This action does not directly affect Canadian access, but illustrates the evolving regulatory attention on peptides internationally
